Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Trial Details

NCT ID

NCT07304739

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Furmonertinib
• Intrathecal chemotherapy
• Stereotactic radiotherapy

Locations (sample)

• Cangzhou, Hebei, China|38.31124,116.85334
• Tianjin, Tianjin Municipality, China|39.14222,117.17667
• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• 18 to 75 years old, male or female;
• Histopathologically confirmed, unresectable, and not amenable to curative radiotherapy treatment-naïve locally advanced or metastatic lung adenocar…
• The patient was confirmed by a local laboratory to have one of the following EGFR mutations :19Del or L858R;
• The patient has not received any systemic anti-tumor treatment in the locally advanced (the researcher judged that it was not suitable for surgery …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.